Type 2 diabetes patients who are prescribed a GLP-1 face daily or weekly injections, resulting in a 50% adherence rate. ITCA 650 is a breakthrough treatment that provides 6 months of dosing in one treatment.
‘Rewrite the script’ was the launch campaign that invited HCPs to rewrite how they treat type 2 diabetes and to change the patient conversation to one of successful disease management.